1 Failure to achieve complete resolution |
1 |
|
Risk Ratio (M-H, Fixed, 95% CI) |
Totals not selected |
1.1 Face only |
1 |
|
Risk Ratio (M-H, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
2 Failure to achieve complete resolution (long term) |
1 |
|
Risk Ratio (M-H, Fixed, 95% CI) |
Totals not selected |
2.1 Face only |
1 |
|
Risk Ratio (M-H, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
3 Decrease in erythema score |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
3.1 Face only |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
4 Decrease in erythema score (long term) |
1 |
|
Mean Difference (IV, Random, 95% CI) |
Totals not selected |
4.1 Face only |
1 |
|
Mean Difference (IV, Random, 95% CI) |
0.0 [0.0, 0.0] |
5 Erythema - Failure to achieve complete resolution |
1 |
|
Risk Ratio (M-H, Fixed, 95% CI) |
Totals not selected |
5.1 Face only |
1 |
|
Risk Ratio (M-H, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
6 Decrease in scaling score |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
6.1 Face only |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
7 Decrease in scaling score (long term) |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
7.1 Face only |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
8 Scaling - Failure to achieve complete resolution |
1 |
|
Risk Ratio (M-H, Fixed, 95% CI) |
Totals not selected |
8.1 Face only |
1 |
|
Risk Ratio (M-H, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
9 Side effects |
1 |
|
Risk Ratio (M-H, Fixed, 95% CI) |
Totals not selected |
9.1 Face only |
1 |
|
Risk Ratio (M-H, Fixed, 95% CI) |
0.0 [0.0, 0.0] |